Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 11 Prostatic Neoplasms 7 Neoplasm Metastasis 5 Ovarian Neoplasms 4 Neoplasms 4 Triple Negative Breast Neoplasms 3 Endometrial Neoplasms 3 Small Cell Lung Carcinoma 2 Fallopian Tube Neoplasms 2 mCRPC 1 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Pheochromocytoma 1 Pathologic Complete Response 1 Paraganglioma 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 46 Gemcitabine 23 enfortumab vedotin 22 Nivolumab 20 Cisplatin 17 avelumab 16 Magnetic Resonance Spectroscopy 16 Carboplatin 14 atezolizumab 13 Specimen Handling 12 Docetaxel 11 sacituzumab govitecan 9 Paclitaxel 8 Ipilimumab 8 durvalumab 6 Mitomycin 5 Fluorodeoxyglucose F18 5 cabozantinib 4 Taxes 4 toripalimab 3 pemigatinib 3 erdafitinib 3 X-Rays 3 Radiosurgery 3 Platinum 3 Pemetrexed 3 Immunoglobulin G 3 CTLA-4 Antigen 3 Biopsy 3 ALT-803 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × talazoparib × 1 year × Clear all

NCT04678362 2025-09-22

TALASUR

Centre Francois Baclesse

Phase 2 Recruiting

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡